Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4161/23723548.2014.963445 http://scihub22266oqcxt.onion/10.4161/23723548.2014.963445 C4655600!4655600!26609545     free     free     free Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\26609545.jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Mol+Cell+Oncol 2014 ; 1 (3): ä Nephropedia Template TP {{tp|p=26609545|t=2014. Metabolic vulnerability of KRAS-driven cancer cells |pdf=|usr=}}{{26609545}} gab.com Text Metabolic vulnerability of KRAS-driven cancer cells JO: Mol Cell Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26609545 #FOAvip Interfering with anaplerotic utilization of glutamine (Gln) was recently reported to sensitize KRAS-driven cancer cells to the cytotoxic effects of capecitabine and paclitaxel. This effect was due to bypass of a Gln-dependent G1 cell cycle checkpoint in these cells. This study highlights therapeutic opportunities created by metabolic reprogramming in cancer cells. Twit Text FOAVip Metabolic vulnerability of KRAS-driven cancer cells ????Mol Cell Oncol http://www.kidney.de/pget.php?&tw=1&pmid=26609545 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26609545 #FOAvip English Wikipedia <ref>{{Cite pmid|26609545}}</ref> Metabolic vulnerability of KRAS-driven cancer cells #MMPMID26609545 Foster DA Mol Cell Oncol 2014[Jul]; 1 (3): ä PMID26609545show ga Interfering with anaplerotic utilization of glutamine (Gln) was recently reported to sensitize KRAS-driven cancer cells to the cytotoxic effects of capecitabine and paclitaxel. This effect was due to bypass of a Gln-dependent G1 cell cycle checkpoint in these cells. This study highlights therapeutic opportunities created by metabolic reprogramming in cancer cells. äMetabolic vulnerability of KRAS-driven cancer cells (epmc).pdf DeepDyve Pubget Overpricing